Penang gets the patients; Thailand's ticket is twelve times bigger
HONG KONG, Nov 22, 2026 - (ACN Newswire) - Penang hosted 285,400 medical tourists in 2026H1 at RM2,109 per head. Thailand targets 580,000 patients at twelve times the spend. The gap is case mix, not volume.Penang published its medical tourism numbers on 30 September. The state counted 285,400 m

HONG KONG, Nov 22, 2026 - (ACN Newswire) - Penang hosted 285,400 medical tourists in 2026H1 at RM2,109 per head. Thailand targets 580,000 patients at twelve times the spend. The gap is case mix, not volume.

Penang published its medical tourism numbers on 30 September. The state counted 285,400 medical tourists in the first half of 2026. They spent RM601.8 million in the state's hospitals. Wong Hon Wai, who chairs the state's tourism and creative economy committee, read the figures out himself and called the market a significant one.
The comparison with 2025 is where the numbers start to pull apart. Last year Penang hosted 520,000 medical tourists and collected RM1.14 billion. That works out to RM2,192 per patient. Double the 2026 half-year and Penang is on pace for about 570,800 patients, up 9.8%, and about RM1,203.6 million in revenue, up 5.6%. Revenue per patient falls about 4%.
So the volume engine works and the ticket engine does not. Every extra patient is worth less than the average patient of last year. A market can grow in two ways: more patients, or more money per patient. Penang is collecting the first and missing the second, and the second is where hospital revenue actually comes from.
What RM2,109 actually buys
Two thousand ringgit is a short hospital stay. It covers a consultation package, some diagnostics, maybe a minor procedure and a few nights in a ward. It does not cover a surgical oncology cycle, which runs tens of thousands of dollars in any market that sells one. At the exchange rate implied by the state's own conversion of RM601.8 million into US$143 million, RM2,109 is about US$501 per patient.
Penang medical tourism | 2026 H1 | 2025 full year |
Medical tourists | 285,400 | 520,000 |
Hospital revenue | RM601.8 million | RM1.14 billion |
Revenue per tourist | RM2,109 | RM2,192 |
Share of Malaysia medical tourism | more than one-third | more than one-third |
Source: Bernama
The scope of the count matters here. Wong stated that the figures cover hospitals only. Dental clinics, clinical laboratories, diagnostic centres and pharmacies sit outside them. His office argued that the true total of medical travellers and their spending is therefore higher than the official line. That argument is fair, and it cuts both ways: the RM601.8 million is a floor for the market, and the RM2,109 is also a floor for what each visitor spends. But a floor for spending is not the same thing as a ticket that is rising. The measured number went down against 2025, and nothing in the floor argument changes that direction.
The per-head figure also tells you what kind of patient Penang is attracting. Screening trips, follow-up visits and chronic care top-ups are low-ticket by nature. Complex surgery is high-ticket. An average of RM2,109 means the low-ticket visits outnumber the surgical ones by a wide margin, because one oncology patient paying eighty times the average would need dozens of screening visitors to keep the same mean. Penang has the volume to move that average. It has not moved it.
Where the patients come from explains why the average sits where it does. Indonesia is Penang's largest source market, served by direct flights from Jakarta, Surabaya, Banda Aceh and Medan, with a Batam route added on 18 October. Batam sits under an hour by ferry. A patient who can decide on a Tuesday morning and be in a Penang clinic by Wednesday noon is a patient making a low-commitment purchase. Short-distance, short-decision travel is structurally a screening and follow-up trade. It fills clinics and hotel rooms. It does not fill surgical suites for three weeks.
The same short-haul logic shapes the price. Penang sells internationally accredited hospitals, modern equipment and multilingual staff, and Wong was explicit that competitive pricing is one of the state's attractions. A hospital that wins patients on price collects patients whose procedures carry price-shaped margins. The state's selling points are real, and every one of them is a volume argument rather than a ticket argument.
The hospital's own accounts make the flat ticket costly in a way the topline hides. An operating theatre, an imaging suite and an intensive care bed cost the same to run whether they are filled by a screening patient or by a surgical one. Beds are the scarce asset, and each bed-night earns whatever the occupant bought. The volume model spends bed-nights at low yield, which is tolerable only while beds are abundant. The ticket model raises the yield of every bed-night the hospital already owns. When occupancy tightens, the two models stop being merely different and start being opposed: a theatre slot given to a routine endoscopy is a slot no longer available for the tumour resection that pays ten times as much. Penang's hospitals are not short of demand today. The numbers above show the strain arriving on schedule: the patient count is compounding faster than the revenue per patient, which means the cheapest visits are consuming a growing share of the same fixed asset base.
The twelve-times ticket next door
Thailand publishes targets rather than half-year actuals, and the contrast is still useful. The country's medical tourism plan for 2026 aims at about 580,000 international patients and THB125 billion, which KIRA Research puts at about US$3.5 billion. Per patient, that is about US$6,034. Penang's annualized run rate is about 570,800 patients at about US$501 per head. The headcounts nearly match. The revenue per head differs by a factor of twelve.
2026, one hospital year | Penang annualized | Thailand 2026 target |
International patients | 570,800 | 580,000 |
Revenue | RM1.2 billion | THB125 billion |
Revenue in US dollars | US$501 per patient | US$6,034 per patient |
JCI-accredited hospitals | not disclosed | 61 |
Source: KIRA Research, Bernama
The twelve-fold gap is not explained by patient count, currency or marketing budgets. It is explained by what each patient buys. Thailand's flagship hospitals sell long-stay oncology, cardiac surgery and orthopaedics to patients who stay for weeks. Bangkok's hospital groups built capacity for that trade on purpose: the BDMS group alone runs 58 hospitals with about 9,000 beds, and the country holds 61 JCI-accredited hospitals whose published selling point is prices 30% to 70% below Western equivalents. Cheap by Western standards, expensive per case by Penang's: complex procedures priced a tier above the screening visit, delivered in volume to patients who fly in for them. Thailand prices the complicated case. Penang, on the evidence of its own average, is currently priced as the convenient one.
The regional ledger shows what that positioning is worth. The ASEAN Secretariat's demand report puts Thailand's 2026 medical and wellness tourism market at US$41.95 billion, close to half of the region's US$87.12 billion, with Malaysia at US$14.02 billion. The same report projects the regional market to US$172.15 billion by 2032, a 12.7% annual growth rate. Most of the Malaysian share, on the hospital evidence above, is not being earned in Penang at high-ticket rates.
ASEAN medical and wellness tourism, 2026 | Market size |
Thailand | US$41.95 billion |
Malaysia | US$14.02 billion |
Vietnam | US$8.38 billion |
Indonesia | US$7.86 billion |
ASEAN total | US$87.12 billion |
Source: ASEAN Secretariat
The comparison has a caveat worth stating plainly. Thailand's figure is a policy target, not an audited actual, and "medical and wellness tourism" is a wider basket than Penang's hospital-only count. Market reports show how wide: Stats N Data puts Malaysia's 2026 medical tourism services revenue at US$6.3 billion, forty-four times Penang's half-year hospital figure. Two readings of one industry differ by a factor of forty-four, which is what happens when a definition stretches from hospital bills to spa packages and travel spend. The honest use of these numbers is directional. Thailand aims twelve times higher per patient than Penang currently collects. Even at half its target, it would still aim six times higher.
One more comparison risk sits inside Penang's own figures. The half-year average is set against a full-year average, and hospital case mix is seasonal: screening travel peaks with holiday periods, elective surgery follows insurer and employer calendars. A different H1 mix could move the per-head figure by a few percent in either direction without any real change in the ticket. The 2025 full-year number has the same exposure on the other side, so the direction of the comparison is probably right even if its size is soft. That is why the falsifiable conditions below are written on annual figures, not half-year ones: they test the trend, which is what the argument actually rests on.
Where the extra ringgit would come from
Revenue per patient has three levers: what the patient buys, what it costs, and how long the stay lasts. Penang's published strengths pull in one direction on all three. The state markets internationally accredited institutions, modern equipment, multilingual staff and competitive prices. Wong was explicit that price is one attraction among several, and the competitive price is precisely what keeps the average ticket near RM2,100. A hospital that wins patients on price collects patients whose procedures carry price-shaped margins.
The upgrade path runs through case mix. Oncology, orthopaedics and structured screening programmes carry tickets many times above the current average, and each one needs the same inputs: capital equipment, specialist recruitment and referral chains that deliver diagnosed patients. None of those inputs arrive with an advertising campaign. A linear accelerator costs millions of ringgit and takes months to commission. A bone marrow transplant unit needs credentialed haematologists who currently have choices about where to work. The hospitals that moved their average ticket up, in Thailand and Singapore, did it by building the complex-care stack first and letting the referral flow follow.
There is a funnel logic that makes the upgrade harder than it sounds. Screening visits are supposed to be the top of the funnel: a patient comes for a check, a scan finds something, and the treatment escalates into a high-ticket case. The funnel only works if the escalated treatment happens where the screening happened. Penang's funnel leaks in the middle, because an Indonesian patient with an abnormal scan can now take the result to a growing domestic hospital, and a Thai or Singaporean alternative is a flight away for anyone with serious money. A state that captures the check-up and loses the surgery keeps the RM2,109 visits and donates the RM40,000 cases to competitors. That is the arithmetic hiding inside a flat average.
The primary stakeholders here are Penang's private hospital groups, the operators who serve the international patients behind these figures. Their interest is direct. At the annualized count of about 570,800 patients, every RM200 added to the per-patient ticket is worth about RM114 million a year, revenue that arrives without a single extra flight or hotel night. The same operators are the first to lose if the volume engine stalls, because beds and theatre slots sit idle long before the accounting catches up. A higher ticket protects them on both sides: it grows revenue without adding patient volume, and it builds a margin buffer for the year when Indonesian arrivals dip.
The channels that bring patients in decide which tier they land in, and the two main channels pull in opposite directions. Agent-led travel, the dominant channel for short-haul Indonesian trips, is built around packages: fixed itineraries, negotiated rates, volume commissions. Packages standardize the purchase and cap the ticket, because the agent's margin depends on keeping the bundle cheap and repeatable. Doctor-led referral works the other way. A physician in Surabaya who trusts a specific Penang oncologist sends the complicated case directly, and the arriving patient books whatever the disease requires rather than what a package contains. Building that second channel is unglamorous work: liaison offices in Indonesian cities, continuing-education visits for provincial specialists, corporate and insurance contracts that route employees to a named hospital. It is also the only channel that reliably delivers high-ticket patients, because complex cases follow trust rather than price. The hospitals that raised their per-patient revenue in Bangkok did it by investing in exactly this referral infrastructure, years before the revenue appeared.
There is also a pricing ladder a hospital can climb without touching its headline prices. A screening product can be tiered from a basic panel to an executive full-body programme; the same scanner, the same morning, three different tickets. Single-specialty packages let a patient buy a defined episode of care, from cataract surgery to a cardiac workup, at a published rate that sits well above the walk-in average. None of this requires new buildings. It requires the discipline to productize what the hospital already does, and the willingness to stop selling every visiting patient the same cheapest bundle. The flat RM2,109 average suggests Penang's hospitals, collectively, have not yet made that move, or have made it for too small a slice of their foreign book.
Currency is a lever Penang does not control and cannot rely on. Foreign patients pay from rupiah, baht or dollars, and a weaker ringgit makes the same RM2,100 bill cheaper for them without the hospital changing anything. That effect lifts arrivals, which is how the volume engine gets its fuel, but it leaves the ringgit-denominated ticket exactly where it was. A hospital cannot book a margin improvement on exchange rates. The ticket has to move in ringgit, through what the patient buys, or it does not move at all.
That second risk is not hypothetical, because the state government itself has named it.
The neighbours are pouring concrete
Wong's September statement contains its own warning. Vietnam, Thailand and Pakistan, he said, are actively developing their medical tourism industries, and Penang needs to diversify its source markets beyond Indonesia. A state official publicly listing his own competitors is the clearest evidence in this file that the volume engine faces pressure from below.
The pressure shows up in domestic capacity, in three countries at once. Indonesia, Penang's largest source market, budgeted IDR4.7 trillion (about US$287.9 million) for its free health screening programme in 2026, on top of a BPJS insurance scheme that already covers 221 million people. Indonesia also accounts for 24.89% of ASEAN's telehealth revenue in 2025, the largest share in the region. A patient who gets screened, insured and treated at home is a patient who does not fly to Penang for a RM2,100 visit. The screening programme is the sharper threat, because it hands every Indonesian a free version of the exact service Penang sells to Indonesian visitors.
Vietnam is building too: An Giang province, on the border that much of Penang's southern patient flow crosses, expanded a medical centre from 160 to 192 beds and broke ground on a 300-bed facility funded with VND680 billion. And Thailand, the regional leader, is deepening its own base: the Asian Development Bank lent US$212 million to upgrade five public hospitals serving 14 million people outside Bangkok, a loan that puts subsidised capital behind specialist care in exactly the mid-market segment Penang serves. Bangkok is also pushing its medical investment hub programme, with a target of THB68 billion in new health-sector investment, at least 0.5% of added GDP and THB100 billion in economic output. Thailand is not defending its lead with hospitals it already has. It is buying more.
None of this overturns the argument, but each piece moves its timeline. Capacity projects run for years before they change patient behaviour. Penang's Indonesian flow rests on direct flights from Jakarta, Surabaya, Banda Aceh and Medan, with the Batam route added on 18 October, and proximity is a real moat for routine care. Wong is also hunting new markets: the Arab region and Australia, sold on Muslim-friendly facilities, beaches and food. Those markets can add patients. Nothing in the diversification plan adds a single ringgit to the per-patient figure, because a new source market arriving for the same RM2,100 visit multiplies the volume problem without touching the ticket problem.
Two details in the competitive picture deserve their own reading. Pakistan, which Wong named alongside Vietnam and Thailand, is not today a regional medical tourism power, and its relevance to Penang's Indonesian corridor is small. Its presence on an official competitor list says something else: the price-sensitive segment of the market is now contested globally, and any destination competing on affordability should expect the competition to come from places with even lower cost bases. Long-haul premium corridors work differently. Arab-region and Australian patients fly further, stay longer and buy bigger procedures, which is why Thailand and Singapore have cultivated those markets for years with dedicated service lines. Winning them is less about beaches and more about whether the cardiac and oncology programmes exist to receive them. The Muslim-friendly packaging Wong describes is the entry ticket; the complex-care stack is the product.
The exposure is specific. The first patients a domestic system keeps at home are the screening and follow-up cases, the RM2,100 visits that make up Penang's volume base. Complex oncology cases, the ones that pay for linear accelerators, leave home last, because they depend on capability that takes longest to build. Penang could therefore lose its low-ticket volume and keep its high-ticket cases, and the state would end up with a smaller, richer book of patients. That outcome would raise the average ticket while shrinking it.
Four readings that would change this one
Each of the following observations, if it arrives, breaks a load-bearing part of the argument above.
First, if revenue per patient prints at or below RM2,200 for full-year 2026 and again for 2027, the low-ticket reading hardens into a trend, and Penang's growth model stands confirmed as a volume model. Second, if oncology and inpatient specialty cases push per-patient revenue above RM2,500 in any reporting period before the end of 2027, the upgrade path is already working and the twelve-times gap is closing faster than this analysis expects. Third, if Penang's share of Malaysia's medical tourism falls below one-third while national totals keep growing, source-market competition is winning and the volume engine itself is at risk. Fourth, if Indonesian arrivals drop after the Batam route settles in, while total volume holds, the diversification problem has arrived before the ticket problem has been solved.
Two of the four readings can be checked from published figures alone, which is worth noting for anyone tracking the state's quarterly statements. The other two need the source-market breakdowns that Wong's office has begun publishing with each release. The data now exists in enough detail to catch the shift early, whichever direction it goes.
The mechanism underneath all four is the same one. Patient counts are the visible part of medical tourism, and Penang is good at them. Revenue per patient is the quiet part, and it moves only when hospitals buy the equipment, recruit the specialists and win the referral chains that high-ticket cases require. The neighbours are buying that equipment now. Two decades of Bangkok's positioning show what the end state looks like: the same patient flow, sold at a different point in the disease. The ringgit per head will show who wins the race to charge more for care, and at RM2,109 against Thailand's target, Penang is currently the cheap ward in a market that pays premium rates for complexity.
Sources
- Bernama: Penang Welcomes 285,400 Medical Tourists, Generates RM601.8 Mln In 1H 2026, 2026-09-30
- ASEAN Secretariat: Demand Report of Health and Wellness Tourism Services in ASEAN, 2026-07
- KIRA Research: Thailand Medical and Wellness Tourism 2026, 2026-01
- Asian Development Bank: ADB provides US$212 million loan to upgrade five public hospitals in Thailand, 2026-10-15
- Vietnam.vn: Tinh Bien Medical Centre digital transformation, An Giang province, 2026-01
- Mordor Intelligence: Telehealth Services Market in ASEAN, 2026-01
- Stats N Data: Global Medical Tourism Services Market Outlook 2026-2033, 2026-01
- Taiwan Trade: Thailand Medical Investment Hub targets THB68 billion in new investment, 2026-01
Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com
Tokyo Overnight
Japan markets, decoded. Get the brief in your inbox.
No spam. Unsubscribe anytime.